Mesoblast Limited (NASDAQ:MESO) Receives $10.83 Average PT from Analysts

Mesoblast Limited (NASDAQ:MESO – Get Rating) has received a consensus rating of “Hold” from the six research firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $10.13.

A number of equities analysts have recently commented on the stock. William Blair assumed coverage on shares of Mesoblast in a research report on Thursday, March 9th. They issued an “outperform” rating and a $8.00 price objective for the company. Jefferies Financial Group cut shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Tuesday, December 6th. Cantor Fitzgerald restated an “overweight” rating and set a $23.00 target price on shares of Mesoblast in a report on Wednesday, February 1st. Finally, Chardan Capital restated a “sell” rating and set a $2.50 target price on shares of Mesoblast in a report on Wednesday, March 1st.

Mesoblast Price Performance

MESO stock opened at $3.26 on Thursday. The firm has a 50 day moving average of $3.35 and a 200-day moving average of $3.17. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.19. Mesoblast has a 12 month low of $2.14 and a 12 month high of $4.94. The firm has a market capitalization of $480.59 million, a P/E ratio of -5.26 and a beta of 3.31.

Mesoblast (NASDAQ:MESO – Get Rating) last released its quarterly earnings data on Monday, February 27th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Mesoblast had a negative net margin of 1,068.42% and a negative return on equity of 16.52%. The firm had revenue of $2.13 million during the quarter, compared to the consensus estimate of $1.50 million. As a group, sell-side analysts predict that Mesoblast will post -0.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mesoblast

A number of hedge funds have recently bought and sold shares of MESO. OLD Mission Capital LLC purchased a new stake in shares of Mesoblast during the 4th quarter valued at about $145,000. Jane Street Group LLC bought a new position in shares of Mesoblast during the 4th quarter valued at approximately $187,000. Millennium Management LLC bought a new position in shares of Mesoblast during the 4th quarter valued at approximately $344,000. Vident Investment Advisory LLC grew its stake in shares of Mesoblast by 12.8% during the 4th quarter. Vident Investment Advisory LLC now owns 28,080 shares of the company’s stock valued at $82,000 after acquiring an additional 3,191 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Mesoblast during the 4th quarter valued at approximately $85,000. Hedge funds and other institutional investors own 2.60% of the company’s stock.

About Mesoblast

(Get Rating)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.